SION-719 failure removes Vertex’s biggest cystic fibrosis threat, Bernstein says
Bernstein said Sionna’s SION-719 Phase 2a trial failed to meet its key efficacy endpoint.
Bernstein said Sionna’s SION-719 Phase 2a trial failed to meet its key efficacy endpoint. Average sweat chloride improved by only -1.0 mmol/L, with a p-value of 0.7, well below the prespecified success threshold of 10 mmol/L. Sionna will no longer advance SION-719 as an add-on therapy to Trikafta.
Bernstein said the result removes the biggest competitive risk hanging over Vertex Pharmaceuticals (VRTX). The market had previously viewed Sionna as a strong challenger to Vertex’s cystic fibrosis franchise. Instead, the negative trial result is a positive catalyst for Vertex, and Bernstein said Vertex’s dominance of the cystic fibrosis market shows “no sign of ending” in the foreseeable future.
The firm’s rationale is that the next competitor would need to surpass not Trikafta, but Vertex’s next-generation drug Alyftrek, raising the competitive bar. Bernstein said Vertex itself is most likely to be its own strongest competitor and could extend its cystic fibrosis leadership beyond the expiration of its patents in 2038.
Bernstein said the outcome is not yet fully priced in and that the negative binary event creates a positive near-term catalyst for Vertex. It is negative for privately held Sionna because of the failure of its core pipeline candidate. Bernstein said the removal of competitive risk could support a valuation recovery.
The catalysts identified in the note are: market absorption of the valuation rerating following the negative SION-719 result; Vertex’s SKYLINE 102/103 trial data, which could support patients switching to Alyftrek and Vanza; progress in Vertex’s next-generation cystic fibrosis drug development, potentially extending beyond the 2038 loss-of-exclusivity date; and progress in Vertex’s non-cystic-fibrosis pipeline, including VX-548 and VX-147.
In summary, Bernstein said the SION-719 failure cleared Vertex’s biggest competitive threat in cystic fibrosis and reinforced its market leadership.
Bernstein said the result removes the biggest competitive risk hanging over Vertex Pharmaceuticals (VRTX). The market had previously viewed Sionna as a strong challenger to Vertex’s cystic fibrosis franchise. Instead, the negative trial result is a positive catalyst for Vertex, and Bernstein said Vertex’s dominance of the cystic fibrosis market shows “no sign of ending” in the foreseeable future.
The firm’s rationale is that the next competitor would need to surpass not Trikafta, but Vertex’s next-generation drug Alyftrek, raising the competitive bar. Bernstein said Vertex itself is most likely to be its own strongest competitor and could extend its cystic fibrosis leadership beyond the expiration of its patents in 2038.
Bernstein said the outcome is not yet fully priced in and that the negative binary event creates a positive near-term catalyst for Vertex. It is negative for privately held Sionna because of the failure of its core pipeline candidate. Bernstein said the removal of competitive risk could support a valuation recovery.
The catalysts identified in the note are: market absorption of the valuation rerating following the negative SION-719 result; Vertex’s SKYLINE 102/103 trial data, which could support patients switching to Alyftrek and Vanza; progress in Vertex’s next-generation cystic fibrosis drug development, potentially extending beyond the 2038 loss-of-exclusivity date; and progress in Vertex’s non-cystic-fibrosis pipeline, including VX-548 and VX-147.
In summary, Bernstein said the SION-719 failure cleared Vertex’s biggest competitive threat in cystic fibrosis and reinforced its market leadership.